COMPANY PROFILE

Laminar Pharma

Explore full profile

Laminar Pharma I Pioneering biopharmaceutical company.

Palma, SpainFounded 2006Biotech & Life Sciences

Valuation $25–50M Last recorded · 2024

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Laminar Pharma

Laminar Pharma is a pioneering biopharmaceutical company focused on the discovery, design, and initial clinical development of a new generation of therapies. The company specializes in creating innovative treatments for highly prevalent diseases such as cancer, Alzheimer's disease, and neuropathic pain, as well as rare and pediatric diseases. Laminar Pharma operates in the biopharmaceutical market, serving patients with unmet clinical needs. The business model revolves around research and development (R&D) of lipid-based therapies, which are then brought to initial clinical trials. Revenue is generated through partnerships, licensing agreements, and potential future sales of successful therapies. The company continuously seeks new collaborations to expand its research and development capabilities.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: Palma, Spain
Employees: 37
Open positions: None listed
Dealroom signal: 66.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Nov 2024	$6.5M	$48M	Alba Pérez Foundation	↗
EARLY VC✓Equity / VC	Oct 2023	$9.7M	$39M	OK Venture	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	Profit	Margin
2026
2025
2024
2023
2022		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Laminar Pharma website traffic

Latest recorded traffic for Laminar Pharma is 1.3K monthly website visits, down 23.5% over the last three months. Laminar Pharma's team declined 2.6% over the past year.

Latest monthly visits1.3K 3-month web change-23.5% 1-year team growth-2.6%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational	—	$5.1M	—
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
KBKOTAI BiotechnologiesHigh-throughput structural modeling and analysis for immune cell sequences	Suita-Shi, Japan	Operational
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational